Sarcopenia Is Associated with Cognitive Decline and Falls but Not Hospitalization in Community-Dwelling Oldest Old in China: A Cross-Sectional Study

Weihao Xu*, Tao Chen*, Qing Shan*, Bo Hu, Ming Zhao, Xinli Deng, Jing Zuo, Yixin Hu, Li Fan

Corresponding Authors: Yixin Hu, e-mail: chhyxcn@126.com; Li Fan, e-mail: fanli301@hotmail.com

Source of support: The study was supported by Military Healthcare Fund (12BJZ40 and 15BJZ41) and Opening Foundation of National Clinical Research Center for Geriatric Diseases (NCRCG-PLAGH-2017010)

Background: The aim of this study was to investigate the association between sarcopenia and cognitive decline, falls, and hospitalization in a Chinese elderly population.

Material/Methods: This cross-sectional survey was conducted between November 2018 and May 2019, and enrolled only older adults aged 80 years or over (oldest old). We diagnosed sarcopenia using the Asian Working Group for Sarcopenia criteria. Demographic characteristics, disease history, smoking status, drinking status, cognitive function, falls, and hospitalization events in the previous 12 months were acquired by face-to-face interview. Cognitive status was evaluated by the Montreal Cognitive Assessment. Falls was ascertained by the question “Have you fallen down in the last 12 months?” Hospitalization was ascertained by the question “Have you received inpatient care in the past year?”

Results: A total of 582 participants (aged 80–99 years and 42.3% male) were included. The prevalence of sarcopenia was 21.7% (95% confidence interval [CI]: 17.3–26.2%) and 33.3% (95% CI: 27.4–39.3%) for females and males, respectively. Among the study population, the prevalence of cognitive decline was 60.8%; the proportions of the oldest old who had falls or hospitalization in the past 12 months were 18.1% and 34.3%, respectively. Multivariate analyses showed that sarcopenia was significantly and independently associated with cognitive decline (odds ratio (OR)=1.96, 95% CI: 1.17–3.27) and falls (OR=2.00, 95% CI: 1.17–3.43) but not associated with hospitalization (OR=1.32, 95% CI: 0.83–2.08).

Conclusions: Our results showed that sarcopenia was significantly and independently associated with cognitive decline and falls, but not associated with hospitalization, in the community-dwelling oldest old.

MeSH Keywords: Accidental Falls • Mild Cognitive Impairment • Sarcopenia

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/919894
Background

Sarcopenia is a clinical syndrome that occurs with advancing age, and is characterized by progressive and generalized loss of muscle mass and corresponding decline in muscle and physical performance [1]. Muscle mass has been found to peak around age 24 years and starts to moderately decline between 24 and 50 years of age [2]. The decrease of muscle mass accelerates between 50 and 80 years of age [2]. In total, a decrease of 40% of muscle mass occurs between the ages of 24 and 80 years [2]. Accordingly, the proportion of elderly people with sarcopenia increases remarkably with aging, from about 1 in 10 people at age 65 years to 1 in 4 at age 75 years, and 1 in 2 at 85 years or over [3].

Sarcopenia can lead to increased risk of falls [4–6], functional decline [7–9], and mortality [10,11]. Although there is a wealth of literature on sarcopenia among older adults in different geriatric settings, few investigations have been conducted in the oldest old population (individuals aged ≥80 years) [12]. The oldest old are the most rapidly growing age group globally [12], which results in a higher burden of sarcopenia. The oldest old, especially those with sarcopenia, are more prone to experience hospitalization, disability, cognitive impairment/dementia, and death [12–14], which creates heavy burdens for families and society. Knowledge of the relationship between sarcopenia and poor health events in the oldest old population is useful for development of clinical and public health programs.

Therefore, we performed a cross-sectional study of a community-based sample of oldest old people in China to determine the associations between sarcopenia and 3 adverse health outcomes (cognitive decline, falls, and hospitalization).

Material and Methods

Study design and participants

This cross-sectional study was conducted in an urban community in Beijing between November 2018 and May 2019. The Ethics Board of the Chinese PLA General Hospital approved the study protocol (Ethics approval number: S2018-102-01). All study participants signed the informed consent.

The inclusion criteria were: 1) age 80 years or over and 2) voluntary participation in this study. The exclusion criteria were: 1) refused to take the handgrip strength test or 6-meter course usual gait speed test; 2) severe cognitive impairment, dementia, or a severe hearing problem and therefore an inability to communicate with interviewers; 3) had an implanted cardiac pacemaker; and 4) terminal cancer.

Definition of sarcopenia

According to the Asian Working Group for Sarcopenia (AWGS) criteria, sarcopenia was diagnosed if participants had low muscle mass plus low muscle strength or low physical performance [15].

Measurement of muscle strength

Handgrip strength (HS) was used to assess muscle strength. Participants were tested 2 times for each hand by a digital hand dynamometer, and the maximum value of 4 tests was analyzed. Sex-adjusted values recommended by AWGS consensus were used to defined low muscle strength (men: <26 kg, women <18 kg) [15].

Measurement of physical performance

Usual gait speed (GS) on a 6-meter course was measured objectively, and used to assess physical performance. Two trials were performed, and the shortest walking time was used to calculate GS and was used in the analyses. GS <0.8 m/s was classified as poor physical performance for both men and women [15].

Muscle mass determination

Skeletal muscle mass was estimated using the bioelectrical impedance analysis (BIA). Skeletal muscle index (SMI) was calculated using the equation: SMI=Appendicular skeletal muscle mass (ASM)/height^2 (kg/m^2). Low muscle mass was defined as SMI <7.0 kg/m^2 and <5.7 kg/m^2 for men and women, respectively [15].

Demography and clinical characteristics

Demographic variables (age, sex, education level, smoking status, drinking status, marital status, and physical activity status) were assessed with a face-to-face interview. Low physical activity was defined as a total walking time for exercise purpose less than 150 min and 120 min per week for men and women, respectively [16]. Diagnoses of specific chronic diseases (including coronary heart disease [CHD], chronic obstructive pulmonary disease [COPD], diabetes, hypertension, osteoarthritis, stroke/transient ischemic attack [TIA], chronic kidney disease [CKD], depression, and tumors of any type) were acquired from the participants and their spouses and children and through a careful review of medical documents.

Geriatric assessment

Difficulty in performing activities of daily living (ADLs) were ascertained by a standardized questionnaire [17]. Participants
having difficulty in performing 1 or more ADL activities (bowels, toilet use, bladder transfer, grooming, feeding, mobility, stairs, dressing, and bathing) were classified as having ADL disability. Cognitive function status was measured using the Montreal Cognitive Assessment (MoCA) [18].

**Outcomes**

Outcomes of interest included cognitive decline, falls, and hospitalization. Cognitive decline was defined as MoCA scores of ≤24 and ≤23 for participants aged 80–90 and ≥90, respectively [19]. A fall was defined as an accidental event that caused the participant to unintentionally fall to the floor or other lower levels, and not because of an intrinsic event [20]. Occurrence of falls was ascertained by the question “Have you fallen down in the past 12 months?” Hospitalization was ascertained by the question “Have you received inpatient care in the past year?”

**Statistical analysis**

We reported and compared baseline characteristics of included participants according to the presence or absence of sarcopenia, using the chi-square test for categorical data and one-way analysis of variance (ANOVA) or a nonparametric test for continuous data. We used logistic regression models to examine the associations between sarcopenia and each outcome (cognitive decline, falls, and hospitalization). We included age and sex in the minimally adjusted models, and we used education level, marital status, smoking status, drinking status in the past year, physical activity status, hypertension, diabetes, CHD, stroke/TIA, COPD, osteoarthritis, CKD, tumors of any type, depression, and BMI in the fully adjusted models. Statistical analyses were performed using SPSS 24.0 for Windows (SPSS, Inc., Chicago, IL).

**Results**

**Characteristics of the participants**

Overall, 582 participants were included in our study, including 246 men (42.3%) and 336 women (57.7%). The age range of the included participants was 80–99 years (mean=86.4, SD=3.5 years). Among the study population, the prevalence of cognitive decline was 60.8%; the proportions of the oldest old who had falls or hospitalizations in the past 12 months were 18.1% and 34.3%, respectively. Baseline characteristics of included participants are summarized in Table 1. In general, participants defined as having sarcopenia were found to be older, with a higher proportion of males, low physical activity, and COPD than in those defined as not having sarcopenia. We found no significant difference between the 2 groups in education level, smoking status, drinking status, marital status, CHD, diabetes, hypertension, stroke/TIA, osteoarthritis, tumors of any type, CKD, and depression. Additionally, participants diagnosed with sarcopenia had lower HS, GS, BMI, and MoCA scores. Furthermore, participants classified as having sarcopenia had a higher proportion of having an ADL disability, falls, and hospitalization in the previous 12 months. Subjects included in this study were comparable with those excluded (n=82) in terms of socio-demographic, lifestyle, and health characteristics (Table 2).

**Prevalence of sarcopenia in total study population**

A total of 155 (26.6%) oldest old participants were classified as having sarcopenia according to the AWGS algorithm (Figure 1). The prevalence of sarcopenia in males was higher than in females: 33.3% (27.4–39.3%) in males vs. 21.7% (17.3–26.2%) in females. The prevalence of sarcopenia increased remarkably with advancing age: 15.1%, 26.4%, 42.7%, and 63.6% of individuals aged 80–84, 85–89, 90–94, and 95+ years, respectively, had sarcopenia (Figure 2).

**Association between sarcopenia and adverse health outcomes**

After adjustment for multiple confounders, sarcopenia was significantly and independently associated with cognitive decline (odds ratio [OR]=1.96; 95% confidence interval [CI]: 1.17–3.27) and falls (OR=2.00; 95% CI: 1.17–3.43) (Table 3). Sarcopenia was associated with hospitalization in the crude analysis (OR=1.52; 95% CI: 1.04–2.23) but lost its statistical significance after the inclusion of potential confounders in the multivariate model (OR=1.32; 95% CI: 0.83–2.08) (Table 3).

**Discussion**

The present study explored the association between sarcopenia, as diagnosed by AWGS criteria, and cognitive decline, falls, and hospitalization in a community-based sample of the oldest old. We found that the odds of cognitive decline were nearly 2 times greater in the oldest old with sarcopenia than in those without. The oldest old with sarcopenia had a 2 times higher likelihood of experiencing falls in the past 12 months. The association between sarcopenia and hospitalization was not significant in our study population after multiple adjustment.

We found a higher prevalence of cognitive decline in the oldest old classified as having sarcopenia. This result is in accordance with a recent meta-analysis that indicated that sarcopenia may represent a risk factor for cognitive decline [21]. The pathological link between sarcopenia and cognitive decline remains unclear, but several mechanisms are speculated to be involved. One possible explanation for this association...
Table 1. Characteristics of study participants.

|                          | Sarcopenia | Non-sarcopenic | P   |
|--------------------------|------------|----------------|-----|
| N (%)                    | 155 (26.6) | 427 (73.4)     |     |
| Age, years               | 87.9±3.7   | 85.9±3.3       | <0.001|
| Female, %                | 73 (47.1)  | 263 (61.6)     | 0.002|
| Education level, %       |            |                |     |
| <High school             | 45 (29.0)  | 118 (27.6)     | 0.889|
| High school              | 38 (24.5)  | 101 (23.7)     |     |
| >High school             | 72 (46.5)  | 208 (48.7)     |     |
| Marital status, %        |            |                | 0.468|
| Married                  | 97 (62.6)  | 253 (59.3)     |     |
| Widowed and other        | 58 (37.4)  | 174 (40.7)     |     |
| Smoking status, %        |            |                |     |
| Current                  | 3 (1.9)    | 9 (2.1)        | 0.838|
| Former                   | 29 (18.7)  | 71 (16.6)      |     |
| Never                    | 123 (79.4) | 347 (81.3)     |     |
| Drinking status in past year, % | | | 0.389|
| ≤1 drink per week        | 3 (1.9)    | 17 (4.0)       |     |
| ≥2 drinks per week       | 10 (6.5)   | 21 (4.9)       |     |
| Never                    | 142 (91.6) | 389 (91.1)     |     |
| Low physical activity, % | 47 (30.3)  | 93 (21.8)      | 0.033|
| Chronic diseases, %      |            |                |     |
| CHD                      | 81 (52.3)  | 229 (53.6)     | 0.769|
| Diabetes                 | 46 (29.7)  | 129 (30.2)     | 0.901|
| Hypertension             | 110 (71.0) | 318 (74.5)     | 0.397|
| Stroke/TIA               | 49 (31.6)  | 108 (25.3)     | 0.129|
| Osteoarthritis           | 52 (33.5)  | 176 (41.2)     | 0.094|
| Tumor of any type        | 35 (22.6)  | 82 (19.2)      | 0.369|
| CKD                      | 20 (12.9)  | 58 (13.6)      | 0.831|
| COPD                     | 41 (26.5)  | 76 (17.8)      | 0.021|
| Depression               | 5 (3.2)    | 19 (4.4)       | 0.512|
| BMI, kg/m²               | 21.9±2.8   | 24.7±3.3       | <0.001|
| HS, kg                   | 20.7±5.5   | 24.4±6.7       | <0.001|
| GS, m/s                  | 0.7±0.2    | 0.9±0.2        | <0.001|
| MoCA score               | 20.6±5.0   | 22.6±4.8       | <0.001|
| ADL disability           | 118 (77.1) | 275 (65.5)     | 0.008|
| Falls in the past 12 months | 35 (22.6) | 65 (15.2)      | 0.038|
| Hospitalization in the past 12 months | 62 (40.0) | 130 (30.4) | 0.030|

CHD – coronary heart disease; TIA – transient ischemic attack; CKD – chronic kidney disease; COPD – chronic obstructive pulmonary disease; BMI – body mass index; HS – handgrip strength; GS – gait speed; MNA – Mini-Nutritional Assessment; MoCA – Montreal Cognitive Assessment; ADL – activities of daily living.
Table 2. Characteristics of the included and excluded participants.

|                                | Total sample N=664 | Included sample N=582 | Excluded sample N=82 | p Value Included vs. Excluded |
|--------------------------------|--------------------|-----------------------|----------------------|-----------------------------|
| Age, years, mean (SD)          | 86.5 (3.5)         | 86.4 (3.5)            | 86.7 (3.5)           | 0.554                       |
| Female, n (%)                  | 387 (58.3)         | 336 (57.7)            | 51 (62.2)            | 0.443                       |
| Education level, %             |                    |                       |                      |                             |
| <High school                   | 182 (27.4)         | 163 (28.0)            | 19 (23.2)            | 0.638                       |
| High school                    | 159 (23.9)         | 139 (23.9)            | 20 (24.4)            |                             |
| >High school                   | 323 (48.6)         | 280 (48.1)            | 43 (52.4)            |                             |
| Marital status, %              |                    |                       |                      | 0.228                       |
| Married                        | 405 (61.0)         | 350 (60.1)            | 55 (67.1)            |                             |
| Widowed and other              | 259 (39.0)         | 232 (39.9)            | 27 (32.9)            |                             |
| Smoking status, %              |                    |                       |                      |                             |
| Current                        | 12 (1.8)           | 12 (2.1)              | 0 (0.0)              | 0.262                       |
| Former                         | 118 (17.8)         | 100 (17.0)            | 18 (22.0)            |                             |
| Never                          | 534 (80.4)         | 470 (80.8)            | 64 (78.0)            |                             |
| Drinking status in past year, %|                    |                       |                      | 0.283                       |
| ≤1 drink per week              | 21 (3.2)           | 20 (3.4)              | 1 (1.2)              |                             |
| ≥2 drinks per week             | 33 (5.0)           | 31 (5.3)              | 2 (2.4)              |                             |
| Never                          | 610 (91.9)         | 531 (91.2)            | 79 (96.2)            |                             |
| Low physical activity, %       | 173 (26.1)         | 139 (23.9)            | 34 (41.5)            | 0.001                       |
| Chronic diseases, %            |                    |                       |                      |                             |
| CHD                            | 360 (54.2)         | 310 (53.3)            | 50 (61.0)            | 0.189                       |
| Diabetes                       | 204 (30.7)         | 175 (30.1)            | 29 (35.4)            | 0.330                       |
| Hypertension                   | 493 (74.2)         | 428 (73.5)            | 65 (79.3)            | 0.267                       |
| Stroke/TIA                     | 186 (28.0)         | 157 (27.0)            | 29 (35.4)            | 0.113                       |
| Osteoarthritis                 | 263 (39.6)         | 228 (39.2)            | 35 (44.3)            | 0.389                       |
| Tumor of any type              | 129 (19.4)         | 117 (20.5)            | 12 (15.2)            | 0.271                       |
| CKD                            | 91 (13.7)          | 78 (13.4)             | 13 (15.9)            | 0.546                       |
| COPD                           | 139 (21.2)         | 117 (20.2)            | 22 (27.8)            | 0.121                       |
| Depression                     | 29 (4.4)           | 24 (4.2)              | 5 (6.3)              | 0.377                       |
| BMI, kg/m²                     | 24.0 (3.4)         | 23.9 (3.4)            | 24.7 (3.7)           | 0.082                       |

SD – standard deviation; CHD – coronary heart disease; TIA – transient ischemic attack; CKD – chronic kidney disease; COPD – chronic obstructive pulmonary disease; BMI – body mass index.
is that muscle performance may be a kind of indirect reflection of nervous system functional status, which could also be reflected by cognitive function. Salthouse et al. [22] found a significant relationship between slow reaction time and poor cognitive function. Additionally, a previous study [23] indicated that poorer physical performance was significantly associated with poorer cognitive performance in older adults. Another possible cause for the correlation between sarcopenia and cognitive decline is the possible existence of a common intervening factor, such as high oxidative stress status, high inflammatory markers levels, and low sex corticosteroid levels [24–27]. Previous studies showed that these blood markers were associated with both muscle loss and cognitive decline. However, recent studies exploring the association between sarcopenia and cognitive function decline mainly have had a cross-sectional design, from which we could not conclude the causal association. Therefore, studies using a prospective design are needed to clarify this association.

Falls in older adults can cause serious outcomes, such as femoral or hip fractures, which causes the patients to be bedridden and potentially cause further increased risks of deep venous thrombosis and pneumonia. We found that the oldest old with sarcopenia had a 2 times higher likelihood of falls than in those without. This result was in line with previous studies conducted in community-dwelling settings, which found that sarcopenia was a strong predictor of falls [4–6]. In an Italian oldest old study, sarcopenia was even associated with a nearly 3.5 times higher risk of falls [28]. These results support the
view that aging-related loss of skeletal muscle mass is an independent risk factor of falls. Therefore, screening for sarcopenia should be considered when fall risk assessment is performed.

Results of studies investigating the association between sarcopenia with hospitalization have been controversial. Legrand et al. performed a study of 560 oldest old, and found that muscle mass was not associated with hospitalization during a mean follow-up period of 33.5 months [29]. Results from the InCHIANTI study showed that sarcopenia following the EWGSOP definition was associated with increased risk of hospital admission during a 55-month follow-up period [30]. Of note, only sarcopenia defined as low muscle mass plus low grip strength was associated with increased risk of hospital admission; sarcopenia defined as low muscle mass plus low gait speed was not correlated with increased risk of hospital admission [30]. In our study population of community-dwelling oldest old, sarcopenia was not associated with hospitalization.

Our study results have several practical applications. First, the association between sarcopenia and cognitive decline may suggest a new pathophysiological mechanism of cognitive disease, and also suggests to geriatric clinicians that effective interventions to avoid or treat sarcopenia may also be helpful for cognitive function. Second, the association between sarcopenia and falls should remind geriatric clinicians that screening for sarcopenia can help identify the older adults at higher risk for falls, and that early interventions for sarcopenia are of great importance in reducing risk of falling in the elderly.

Our study has several limitations. First, this was a cross-sectional study; thus, we could not clarify the causal relationship between sarcopenia and cognitive decline. Future research with a prospective design is needed to substantiate this possible relationship. Second, the accuracy of muscle mass measurements through BIA is subject to participant conditions, such as dehydration, which is common among older adults. In dehydrated subjects, body fat might be underestimated and fat-free mass might be overestimated, leading to underestimation of the number of participants who have sarcopenia. Third, our study participants were enrolled from a high-income urban community and through a convenience sampling method, which limits the generalizability of our study results.

### Conclusions

The oldest old with sarcopenia had a higher prevalence of cognitive decline and falls. Given the paucity of data on sarcopenia among the Chinese oldest old, our study may serve as a basis for future research aimed at identifying behavioral and psychosocial predictors of sarcopenia, and could help in designing interventions for treating sarcopenia in China.

### Acknowledgements

The authors would like to thank the staff (JXL, LQZ, JS, LNW, SSD, and YL) and participants of this study.

---

**Table 3. Association between sarcopenia and adverse health consequences.**

|                          | Unadjusted       | Minimally adjusted* | Fully adjusted** |
|--------------------------|------------------|---------------------|------------------|
| Cognitive decline        | 2.07 (1.31–3.27) | 2.09 (1.32–3.33)    | 1.96 (1.17–3.27) |
| Falls in past 12 months  | 1.62 (1.03–2.57) | 1.90 (1.17–3.07)    | 2.00 (1.17–3.43) |
| Hospitalization in past 12 months | 1.52 (1.04–2.23) | 1.41 (0.94–2.10)    | 1.32 (0.83–2.08) |

* Adjusted for age and sex; ** adjusted for age, sex, smoking status, drinking status in the past year, marital status, education level, physical activity status, coronary heart disease, stroke/transient ischemic attack, diabetes, chronic obstructive pulmonary disease, chronic kidney disease, hypertension, osteoarthritis, depression, tumor of any type, and body mass index.
References:

1. Marty E, Liu Y, Samuel A et al: A review of sarcopenia: Enhancing awareness of an increasingly prevalent disease. Bone, 2017; 105: 276–86

2. Lexell J, Taylor CC, Sjöström M: What is the cause of the ageing atrophy? Total number, size and proportion of different fiber types studied in whole vastus lateralis muscle from 15- to 83-year-old men. J Neurol Sci, 1988; 84: 275–94

3. Yamada M, Nishiguchi S, Fukutani N et al: Prevalence of sarcopenia in community-dwelling Japanese older adults. J Am Med Dir Assoc, 2013; 14: 911–15

4. Scott D, Sanders KM, Aitken D et al: Sarcopenic obesity and dynapenic obesity: 5-year associations with falls risk in middle-aged and older adults. Obesity, 2014; 22: 1568–74

5. Tanimoto Y, Watanabe M, Sun W et al: Sarcopenia and falls in community-dwelling elderly subjects in Japan: Defining sarcopenia according to criteria of the European working group on sarcopenia in older people. Arch Gerontol Geriatr, 2014; 59: 295–99

6. Matsumoto H, Taninura C, Tanishima S et al: Sarcopenia is a risk factor for falling in independently living Japanese older adults: A 2-year prospective cohort study of the GAINA study. Geriatr Gerontol Int, 2013; 13: 958–63

7. Cawthon PM, Blackwell TL, Cauley J et al: Evaluation of the usefulness of consensus definitions of sarcopenia in older men: Results from the observational osteoporotic fractures in men cohort study. J Am Geriatr Soc, 2015; 63: 2247–59

8. Tanimoto Y, Watanabe M, Sun W et al: Association of sarcopenia with functional decline in community-dwelling elderly subjects in Japan. Geriatr Gerontol Int, 2013; 13: 958–63

9. Woo J, Leung J, Morley JE: Defining sarcopenia in terms of incident adverse outcomes. J Am Med Dir Assoc, 2015; 16: 247–52

10. Vetrano DL, Landi F, Volpato S et al: Association of sarcopenia with short-and long-term mortality in older adults admitted to acute care wards: Results from the CRIME study. J Gerontol A Biol Sci Med Sci, 2014; 69: 1154–61

11. Landi F, Cruz-Jentoft A, Lijnen H et al: Cellular and molecular mechanisms of sarcopenia: A comprehensive review. J Am Geriatr Soc, 2013; 61: 203–9

12. Zeng Y, Feng Q, Hesketh T et al: Sarcopenia and mortality risk in frail older persons aged 80 years and older: Results from the SIRENTE study. Age Ageing, 2013; 42: 203–9

13. Zeng Y, Feng Q, Hesketh T et al: Survival, disabilities in activities of daily living, and physical and cognitive functioning among the oldest-old in China: A cohort study. Lancet, 2017; 389: 1619–29

14. Legrand D, Vaes B, Mathei C et al: Muscle strength and physical performance as predictors of mortality, hospitalization, and disability in the oldest old. J Am Geriatr Soc, 2014; 62(6): 1030–38

15. Yang Z, Slavin M, Sachdev PS: Dementia in the oldest old. Nat Rev Neurol, 2013; 9(7): 382–93

16. Chen LK, Liu LK, Woo J et al: Sarcopenia in Asia: Consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc, 2014; 15: 95–101

17. Geriatric Medicine Branch of Chinese Medical Association: [Chinese expert consensus on assessment and intervention for elderly patients with frailty] Chinese Journal of Geriatrics, 2017; 36(3): 251–56 [in Chinese]

18. Mahoney FL, Barthel DW: Functional evaluation: The Barthel index. Md State Med J, 1965; 14: 61–65

19. Nasreddine ZS, Phillips NA, Bédirian V et al: The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J Am Geriatr Soc, 2005; 53: 695–99

20. Tan JP, Li N, Gao J et al: Optimal cutoff scores for dementia and mild cognitive impairment of the Montreal Cognitive Assessment among elderly and oldest-old Chinese population. J Alzheimers Dis, 2015; 43: 1403–12

21. Beauchet O, Dubost V, Revel Delhom C et al: French Society of Geriatrics and Gerontology: How to manage recurrent falls in clinical practice: Guidelines of the French Society of Geriatrics and Gerontology. J Nutr Health Aging, 2011; 15: 79–84

22. Cabett Cipolli G, Sanches Yassuda M, Aprahamian I: Sarcopenia is associated with cognitive impairment in older adults: A systematic review and meta-analysis. J Nutr Health Aging, 2019; 23: 525–31

23. Saltzhouse TA: The processing-speed theory of adult age differences in cognition. Psychol Rev, 1996; 103: 403–28

24. Rosano C, Simonsick EM, Harris TB et al: Association between physical and cognitive function in healthy elderly: The Health, Aging and Body Composition Study. Neuroepidemiology, 2005; 24: 8–14

25. Cesari M, Penninx BW, Pahor M et al: Inflammatory markers and physical performance in older persons: The InCHIANTI study. J Gerontol A Biol Sci Med Sci, 2004; 59A: 242–48

26. Szule P, Duboeuf F, Marchand F, Delmas PD: Hormonal and lifestyle determinants of appendicular skeletal muscle mass in men: the MINOS study. Am J Clin Nutr, 2004; 80: 496–503

27. Hovestort E, Bandelow S, Combrinck M, Smith AD: Low free testosterone is an independent risk for Alzheimer’s disease. Exp Gerontol, 2004; 39: 1633–39

28. Weaver JD, Huang MH, Albert M et al: Interleukin-6 and risk of cognitive decline. MacArthur Studies of Successful Aging. Neurology, 2002; 59: 371–78

29. Tanimoto Y, Watanabe M, Sun W et al: Sarcopenia and falls in community-dwelling elderly subjects in Japan: Defining sarcopenia according to criteria of the European Working Group on Sarcopenia in Older People. Arch Gerontol Geriatr, 2014; 59: 295–99

30. Legrand D, Vaes B, Mathei C: Muscle strength and physical performance as predictors of mortality, hospitalization, and disability in the oldest old. J Am Geriatr Soc, 2014; 62: 1030–38

31. Bianchi L, Ferrucci L, Cherubini A et al: The predictive value of the EWGSOP definition of sarcopenia: Results from the InCHIANTI study. J Gerontol A Biol Sci Med Sci, 2016; 71: 259–84